Dr. Smith Apisarnthanarax, MD

Dr. Apisarnthanarax practices at Fred Hutchinson Cancer Center in Seattle, Washington, part of Fred Hutchinson Cancer Center.

Dr. Apisarnthanarax's NPI, 1184839722, was assigned on May 14, 2007. Dr. Apisarnthanarax graduated from The Warren Alpert Medical School of Brown University in 2002. Dr. Apisarnthanarax's Washington license number on file is MD60335889.

Dr. Apisarnthanarax's primary practice is Fred Hutchinson Cancer Center, at 825 Eastlake Avenue East, Seattle, WA 98109.

Dr. Apisarnthanarax's primary practice is Fred Hutchinson Cancer Center in Seattle, Washington, part of Fred Hutchinson Cancer Center. Dr. Apisarnthanarax is also affiliated with UW Medical Center - Montlake. The medical group on file is UW Physicians. Dmand AI also links Dr. Apisarnthanarax to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Apisarnthanarax practices, 3 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Apisarnthanarax's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Apisarnthanarax is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Apisarnthanarax's licenses on file in 5 states: Washington, New Jersey, North Carolina, Pennsylvania and Illinois.

Dmand AI lists anal cancer radiation, cancer radiation-upper GI, colorectal cancer radiation, head & neck cancer radiation, lung cancer radiation and pancreatic cancer radiation among the conditions Dr. Apisarnthanarax treats.

CMS data shows 1,001 Medicare services from Dr. Apisarnthanarax across 18 procedure codes in 2024, for 261 Medicare patients. Medicare paid $85,231 for them. Every service was in an office.

CMS counts 261 Medicare patients who saw Dr. Apisarnthanarax in 2024. The largest group is 65 to 74, with 150 patients. 67% of them have high cholesterol, and 64% have high blood pressure. 7% are also on Medicaid. Their average risk score is 1.67, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Apisarnthanarax's median patient age at 65, with 46% women.

In 2024, Dr. Apisarnthanarax wrote 27 Medicare Part D claims for 19 patients. 96% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $86 in total drug cost. In 2023, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Apisarnthanarax for performance year 2024, reported through an alternative payment model (APM). Dr. Apisarnthanarax accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Apisarnthanarax as offering telehealth.

Dmand AI links 79 papers to Dr. Apisarnthanarax, published from 2005 to 2025. 2018 was the busiest year, with 11. The most frequent topics are Liver Neoplasms, Proton Therapy and Carcinoma, Hepatocellular. Dr. Apisarnthanarax has published most often in Int J Radiat Oncol Biol Phys. Dr. Apisarnthanarax's most frequent co-authors are Stephanie Kelly Schaub, MD, Ramesh Rengan, MD, PhD and Christopher Leigh Hallemeier, MD.

Dmand AI links Dr. Apisarnthanarax to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Cholangiocarcinoma and Thrombosis.

CMS Open Payments shows 31 general payments to Dr. Apisarnthanarax from 7 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 65% of the total. Covidien LP paid the most, $11,346.

Dmand AI lists 1 award for Dr. Apisarnthanarax, most recently CMS Stage 1 EHR in 2012.

Dr. Apisarnthanarax graduated from The Warren Alpert Medical School of Brown University in 2002.

Dr. Apisarnthanarax is in network with 18 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.